Literature DB >> 3119713

Internalization of interleukin 2 (IL-2) by high affinity IL-2 receptors is required for the growth of IL-2-dependent T cell lines.

A Kumar1, J L Moreau, M Gibert, J Thèze.   

Abstract

During the growth of interleukin 2 (IL-2)-dependent T cells IL-2 binding is followed by internalization of the complex between IL-2 and the high affinity IL-2 receptor (HA-IL-2R). The respective role of IL-2 binding to HA-IL-2R and internalization of the complex has been examined. Monoclonal antibody 7D4 (IgM) blocks IL-2-dependent T cell growth although it does not affect IL-2 binding to HA-IL-2R. We show here that 7D4 inhibits T cell growth by blocking IL-2 internalization by HA-IL-2R. In contrast, Fab fragments prepared from 7D4 neither block IL-2 internalization nor inhibit T cell growth. Monoclonal 5A2, that recognizes an epitope related to the IL-2 binding site as well as its Fab fragment, inhibits T cell growth and IL-2 internalization. Monoclonal antibody 7D4, because of its pentameric structure, probably aggregates the IL-2R at the T cell surface and therefore prevents it internalization. The data presented in this paper suggest that simple occupancy of HA-IL-2R by IL-2 is not sufficient to transduce the T cell growth signal; this signal is transmitted only after internalization of the IL-2/HA-IL-2R complex.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119713

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  The expansion of human gammadelta T cells in response to Daudi cells requires the participation of CD4+ T cells.

Authors:  J D Fayen; M L Tykocinski
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

2.  The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.

Authors:  H D Volk; O Josimovic-Alasevic; M Gross; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

3.  Hematopoietic growth factor receptors.

Authors:  J H Shieh; M A Moore
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

4.  Increased capacity for interleukin-2 synthesis parallels disease progression in mice infected with Leishmania major.

Authors:  F P Heinzel; R M Rerko; A M Hujer; R A Maier
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

5.  Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor.

Authors:  H Vié; T Gauthier; R Breathnach; M Bonneville; A Godard; J Dietrich; G Karam; M C Gesnel; M A Peyrat; Y Jacques; J P Soulillou
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

6.  Anti-IL-2 receptor monoclonal antibody AMT-13 increases soluble IL-2 receptor levels in vivo.

Authors:  K Burkhardt; T E Mandel; T Diamantstein; M S Loughnan
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

7.  Potentiation of interleukin-2 production and its binding by monoclonal antibodies to the gangliosides GD3 and GD2.

Authors:  S Schibeci; P Hersey; D Cheresh
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis.

Authors:  Yuta Kobayashi; Takuma Sato; Toshiyuki Nagai; Kenji Hirata; Satonori Tsuneta; Yoshiya Kato; Hirokazu Komoriyama; Kiwamu Kamiya; Takao Konishi; Kazunori Omote; Hiroshi Ohira; Kohsuke Kudo; Satoshi Konno; Toshihisa Anzai
Journal:  ESC Heart Fail       Date:  2021-09-12

9.  Regulation of T lymphocyte proliferation. Interleukin 2-mediated induction of c-myb gene expression is dependent on T lymphocyte activation state.

Authors:  A M Churilla; T J Braciale; V L Braciale
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

10.  Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis.

Authors:  Enken Gundlach; Michael Marcus Hoffmann; Antje Prasse; Sonja Heinzelmann; Thomas Ness
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.